SCHEMBL26627792

SCHEMBL26627792

CONc1nc(Cl)ncc1OC

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.47
SMN1; SMN2 Q16637 4/20 0.47
KDM4E B2RXH2 2/20 0.47
PIN1 Q13526 1/20 0.36
PGK1 P00558 1/20 0.35
KMT2A Q03164 3/20 0.35
MAPT P10636 5/20 0.35
L3MBTL1 Q9Y468 5/20 0.35
TDP1 Q9NUW8 2/20 0.35
MEN1 O00255 1/20 0.35
CYP1A2 P05177 1/20 0.35
CYP2D6 P10635 1/20 0.35
CYP2C9 P11712 1/20 0.35
CYP2C19 P33261 1/20 0.35
STK17A Q9UEE5 1/20 0.35
PLA2G1B P04054 1/20 0.34
POLB P06746 1/20 0.34
ATG4B Q9Y4P1 1/20 0.34
HTT P42858 1/20 0.34
AXL P30530 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30462001 1.00 ALDH1A1 (0.47) ALDH1A1SMN1; SMN2KDM4EPIN1PGK1
SCHEMBL14556227 0.83 ALDH1A1 (0.49) ALDH1A1SMN1; SMN2KDM4EPIN1PGK1
SCHEMBL28276692 0.81 ALDH1A1 (0.47) ALDH1A1SMN1; SMN2KDM4EPIN1PGK1
SCHEMBL6623163 0.81 ALDH1A1 (0.47) ALDH1A1SMN1; SMN2KDM4EPIN1PGK1
SCHEMBL20284348 0.81 STK17B (0.40) ALDH1A1SMN1; SMN2KDM4EPIN1KMT2A
SCHEMBL30462029 0.79 KDM4E (0.40) ALDH1A1SMN1; SMN2KDM4EPIN1KMT2A
SCHEMBL26627800 0.79 KDM4E (0.40) ALDH1A1SMN1; SMN2KDM4EPIN1KMT2A
SCHEMBL1442231 0.79 TRPM8 (0.54) ALDH1A1SMN1; SMN2KDM4EPIN1PGK1
SCHEMBL1442559 0.79 PGK1 (0.51) ALDH1A1SMN1; SMN2KDM4EPGK1STK17A
SCHEMBL31368659 0.79 ALDH1A1 (0.45) ALDH1A1SMN1; SMN2KDM4EPIN1PGK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4741386-A1 PYRIMIDINE COMPOUND, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF Jiangsu Yahong Meditech Co., Ltd. (CN) 2026-05-13 EP disclosed
US-20250289799-A1 PYRIMIDINE COMPOUND, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL USE THEREOF JIANGSU YAHONG MEDITECH CO., LTD. (CN) 2025-09-18 US disclosed
EP-4516779-A1 PYRIMIDINE COMPOUND, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL USE THEREOF Jiangsu Yahong Meditech Co., Ltd. (CN) 2025-03-05 EP disclosed
WO-2025007777-A1 PYRIMIDINE COMPOUND, PREPARATION METHOD THEREFOR AND MEDICAL USE THEREOF 江苏亚虹医药科技股份有限公司 2025-01-09 WO disclosed
WO-2023208130-A1 PYRIMIDINE COMPOUND, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL USE THEREOF 江苏亚虹医药科技股份有限公司 2023-11-02 WO disclosed
CN-116496252-A Pyrimidine compound, preparation method and medical application thereof 江苏亚虹医药科技股份有限公司 2023-07-28 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250289799-A1 PYRIMIDINE COMPOUND, METHOD FOR PREPARING SAME, AND PHARMACEUTICAL USE THEREOF USP1, UPP1, UFL1 ALDH1A1 336/4885SMN1; SMN2 2646/4885KDM4E 1951/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.